- Vera Therapeutics Announces Two Oral Presentations at the 61st European Renal Association Congress
- Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
- Vera Therapeutics to Participate at the 44th Annual TD Cowen Health Care Conference
- Vera Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
- Vera Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares in Public Offering of Class A Common Stock
- Vera Therapeutics Announces Pricing of Upsized Public Offering of Class A Common Stock
- Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock
- Vera Therapeutics Presents Positive 72-Week Data Showing eGFR Stabilization in the Phase 2b ORIGIN Clinical Trial OLE in IgA Nephropathy
- Vera Therapeutics Announces Appointment of Industry Veterans Robert Brenner, M.D. as Chief Medical Officer and William D. Turner as Chief Development Officer
- Vera Therapeutics to Host In-Person R&D Day in New York to Present Week 72 Data from Phase 2b ORIGIN Clinical Trial of Atacicept in IgAN on January 25, 2024
More ▼
Key statistics
As of last trade Vera Therapeutics Inc (VERA:NMQ) traded at 40.47, -20.30% below its 52-week high of 50.78, set on Mar 01, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 39.63 |
---|---|
High | 40.56 |
Low | 38.83 |
Bid | 40.42 |
Offer | 40.52 |
Previous close | 40.01 |
Average volume | 1.70m |
---|---|
Shares outstanding | 54.45m |
Free float | 50.13m |
P/E (TTM) | -- |
Market cap | 2.18bn USD |
EPS (TTM) | -2.28 USD |
Data delayed at least 15 minutes, as of Apr 18 2024 15:52 BST.
More ▼